BioSpace News Archive

If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.

In a fourth quarter 2020 financial results announcement made on Monday, Inovio Pharmaceuticals said it has completed enrollment of 400 participants in its Phase II segment of the INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) Phase II/III trial.

The company notes that this decision has no effect on other indications for Keytruda.

DNA Script, a leading pioneer in enabling DNA synthesis on demand, today announced that the company has been selected by GE Research to join a collaboration to develop a rapid response, mobile medical manufacturing platform to enable on-demand production of nucleic acid-based vaccines and therapies.

Charles Strongo, CEO of Global WholeHealth Partners Corp (OTC:GWHP), comments on https://www.cbsnews.com/news/covid-death-toll-united-states-expected-500k-february/ regarding the potential of 500,000 deaths by mid-February, as stated by the incoming director of the Centers for Disease Control.

Aptose Biosciences Inc., a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market.

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in March: Barclay’s Global Healthcare Conference Format: Presentation Date: Wednesday, March 10, 2021 Time: 4:10 p.m. ET Stifel 3 rd Annual CNS Day Format

Eargo, Inc. a medical device company on a mission to improve the quality of life for people with hearing loss, announced the results of its World Hearing Day survey, in celebration of World Hearing Day on March 3.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced that it has entered into a strategic collaboration with Topcon Corporation.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.